to "become the company's most important product line", receiving FDA approval in 1991 In 1985, Termeer became the company's Chief executive officer (CEO) and in 1986, he took the company public. In 1989, Termeer acquired Integrated Genetics, strengthening the company's presence in molecular biology, protein chemistry, carbohydrate engineering, nucleic acid chemistry, and enzymology. 1990s: Product launches and further expansion Following the approval and success of Ceredase in 1991, Genzyme became devoted to finding drugs, involving recombinant human enzymes that would treat enzyme deficiency conditions that were essential to human survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are considered to be orphan drugs. Ceredase was the first effective treatment for Gaucher's disease, a previously rare, untreatable and potentially fatal genetic disorder. At the time, Ceredase also drew criticism for being the most expensive drug ever sold, on average $150,000 per patient a year. In 1991, Genzyme also took IG laboratories, acquired in 1989, public raising $14 million on IPO. Genzyme's also sold off its interest in GENE-TRAK systems for $10 million and acquired Genecore International's diagnostic enzyme division. In 1992, Genzyme acquired Medix Biotech, Inc., a producer and supplier of monoclonal and polyclonal antibodies, immunoassay components, and immunodiagnostic services. In the same year, Genzyme Limited, acquired Enzymatix Ltd and genetics testing laboratory Vivigen. In 1993, the company acquired German distributor of invitro diagnostic kits, Virotech and immunobiological products manufacturer Omni Res srl. In 1994, Genzyme received FDA approval to market Cerezyme, a genetically engineered replacement for Ceredase. The company acquired Sygena Ltd, BioSurface Technology Inc. and TSI Inc.. TSI was acquired by Genzyme Transgenics Corp. which was 73 percent owned by Genzyme. In 1997, the company acquired PharmaGenics, Inc. creating Genzyme Molecular Oncology. In 1999, Genzyme Surgical Products is established within the wider Group. 2000s: diversification In 2000, the company announced its plan to acquire Biomatrix, Inc. In August 2003, the company acquired SangStat Medical Corp. and its principal anti-organ rejection drug named Thymoglobulin for $600 million. In 2004, the company acquired Ilex Oncology Inc. Genzyme acquired several of Impath's laboratories and cancer-testing technologies in May 2004, after Impath sought Chapter 11 bankruptcy protection. In 2005, the company acquired Bone Care International Inc for $600 million. In 2006, the company acquired AnorMED Inc. for $580 million In 2007, the company agreed to acquire Bioenvision for $345 million, motivated by